drugset / Trial / NCT00387023
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Primary Objectives: 1. To evaluate the efficacy of Zevalin for the treatment of low-grade follicular Non-Hodgkin's lymphoma of the orbit or mucosa-associated lymphoid tissue (MALT) of conjunctiva using radiographic imaging, clinical examination (slit lamp biomicroscopy and external examination of the conjunctiva), and external photography whenever possible. 2. To establish the safety profile in this patient population using clinical examination including slit lamp biomicroscopy, and evaluation of the tear film with Schirmer's test. 3. To establish the dosimetry for Zevalin in the orbit in the first 3 patients who agree to undergo dosimetry.
Timeline
- Start
- 2004-02
- Primary completion
- 2012-07
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 0.3 unknown | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 0.4 unknown | Intravenous |